[Federal Register Volume 61, Number 145 (Friday, July 26, 1996)]
[Notices]
[Pages 39141-39142]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-18969]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for U.S. companies and may also be available for licensing.

ADDRESS: Licensing information and copies of the U.S. patent 
applications and issued patents listed below may be obtained by 
contacting Cindy K. Fuchs, J.D., at the Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804; telephone: 301/496-7735 ext 232; fax: 
301/402-0220. A signed Confidential Disclosure Agreement will be 
required to receive copies of the patent applications.

Inhibition of Retroviral LTR Promoters by Calcium Response Modifiers

EC Kohn, LA Liotta, KL Gardner (NCI)
Filed 12 Dec 94
Serial No. 08/353,765

    The pathogenesis of HIV infection can be divided into two phases 
based upon the activity of the HIV virus. The latent phase is 
characterized by low transciptional activity and/or low

[[Page 39142]]

replication frequency of the virus whereas the lytic phase is 
characterized by high transcriptional activity and/or high replication 
frequency. Although the mechanism(s) involved in the switch from the 
latent to lytic phase is not completely understood, inhibition of the 
viral LTR promoter is an important strategy in AIDS treatment. The 
invention concerns the use of the compound carboxyamidotriazole (CAI), 
a calcium response modifier, and structurally related compounds that 
are capable of preventing the activation of the LTR promoter in the 
treatment of HIV infection and AIDS. In addition, CAI has 
antimetastatic properties and currently is being tested in clinical 
trials for the treatment of cancer. A further advantage is that CAI has 
shown no severe side effects during these trials. Therefore treatment 
of AIDS patients with CAI would also allow for the treatment of related 
cancers such as Kaposi's sarcoma. (portfolio: Infectious Diseases--
Therapeutics, anti-virals, AIDS)

Diastereoselective Process Leading to a Key Intermediate for the 
Preparation of Fluorinated Reverse Transcriptase Inhibitors

VE Marquez, JS Driscoll, MA Siddiqui (NCI)
Serial No. 08/189,095 filed 31 Jan 94
U.S. Patent No. 5,498,719 issued 12 Mar 96

    A novel process has been developed for synthesizing a key 
intermediate in the preparation of fluorinated reverse transcriptase 
inhibitors. Recently, several fluorinated dideoxynucleotides have been 
found to be effective inhibitors of reverse transcriptase and, thus, 
offer promise for replacing or augmenting current drugs for the 
treatment of HIV-1 infection; however, chemically synthesizing these 
fluorinated dideoxynucleotides is quite expensive, making it 
economically difficult to produce large-scale amounts for testing. This 
new process allows the synthesis of a key intermediate in the 
production of fluorinated dideoxynucleotides at much lower costs 
because the reaction is diastereoselective, meaning that there are 
fewer side reactions and more primary product is produced. (portfolio: 
Infectious Diseases--Therapeutics, anti-virals, AIDS)

C-C Chemokines That Inhibit Retrovirus Infection

P Lusso, R Gallo, F Cocchi, A De Vico, A Garzino-Demo (NCI)
Filed 30 Nov 95
DHHS Reference No. E-008-96/0

    This invention concerns three members of the human C-C chemokine 
family, RANTES, macrophage inflammatory protein 1 (MIP-
1) and macrophage inflammatory protein 1 (MIP-
1), which are produced and secreted by several cell types, 
including CD8-positive T lymphocytes, and which act in vitro as HIV 
suppressive factors. These factors and their respective genes may be 
used in the diagnosis, prognosis, treatment and prevention of AIDS and 
other retrovirus-induced diseases. The invention provides a therapeutic 
preparation, methods for therapeutic and prophylactic treatment of 
retroviral infection, and a method of prognosis for retroviral 
infection. The technology was reported in BioWorld Today (6(234):1 
(December 7, 1995) and Science 270(8):1560-1561 (December 8, 1995). 
(portfolio: Infectious Diseases--Therapeutics, anti-virals, AIDS; 
Infectious Diseases--Diagnostics, viral, AIDS)

    Dated: July 16, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-18969 Filed 7-25-96; 8:45 am]
BILLING CODE 4140-01-M